AstraZeneca is soon to publish results from its pre-exposure prophylaxis trial about anti-Covid antibodies given IM to people with comorbid states that reduce the immune response from vaccines. Reduced severe symptomatic risk (relative) by 77%.

Medical Mythbusting Commentary for August 23, 2021

COVID-19 Antibody Treatment Reduces Risk Of Symptomatic Cases By 77 Percent